January 24, 2021

FabiFlu: Glenmark to launch greater power of FabiFlu for gentle and average signs of Covid-19



New Delhi: Drug agency Glenmark Prescribed drugs on Thursday stated it is going to launch a 400 mg model of oral antiviral drug FabiFlu for the therapy of gentle and average COVID-19 in India. Presently, the drug is obtainable in 200 mg dosage.

The corporate, nonetheless, didn’t disclose the value at which it is going to be promoting the drug.

The upper power will enhance compliance for sufferers by successfully decreasing the variety of tablets required per day, Glenmark stated in a press release.

With the brand new 400 mg model, sufferers will now have a extra relaxed dosage routine, with 9 tablets required on Day 1 (4.5 within the morning and 4.5 within the night), and thereafter 2 tablets twice a day from Day 2 until the top of the course, it added.

Glenmark is the primary firm in India to have obtained regulator Medicine Controller Normal of India’s approval for the 400 mg dosage kind, the assertion stated.

“The 200 mg dosage of FabiFlu was developed in keeping with world formulations of the drug Favipiravir, which had comparable power. The 400 mg model is a results of Glenmark’s personal R&D (analysis and growth) efforts to enhance therapy expertise for sufferers in India,” stated Monika Tandon, vice-president and head of scientific growth, world specialty/branded portfolio at Glenmark Prescribed drugs.

The corporate has additionally commenced a post-marketing surveillance research on FabiFlu to intently monitor the efficacy and security of the drug in a big pool of sufferers prescribed with the oral antiviral Favipiravir, the assertion stated.

Shares of Glenmark Prescribed drugs had been buying and selling at Rs 460.15 per scrip on the BSE, up 2.83 per cent from its earlier shut.